Initiating Biologics in Atopic Dermatitis: Global Practices and Recommendations from the AMAZE Project - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Global Approaches and Expert Recommendations for Starting Biologics in Atopic Dermatitis: Findings from the AMAZE Project

  • By

  • April W. Armstrong

  • Hyun Jung Kim

  • Andrew E. Pink

  • Joe Gorelick

  • Mariateresa Rossi

  • Magdalena Trzeciak

  • Mette Deleuran

  • Saeko Nakajima

  • Vimal H. Prajapati

  • October 19, 2026

Share

  • 1

    The AMAZE project examined real-world practices and challenges in initiating and managing biologics for moderate-to-severe atopic dermatitis.

  • 2

    A worldwide survey of 150 dermatologists found substantial variation in biologic initiation and management, including treatment transitions, follow-up timing, and expected treatment duration.

  • 3

    Clinicians used overlapping therapy, direct switches, or washout periods when transitioning patients from conventional systemic therapies to biologics.

  • 4

    Experts recommended defining patient-centered treatment goals and tailoring transition strategies when switching therapies.

  • 5

    Experts recommended assessing response at approximately 12 to 16 weeks and continuing background topical therapy to address flares and support long-term disease control.

Original Source(s)

Initiating Biologics in Atopic Dermatitis: Global Practices and Recommendations from the AMAZE Project

  • by April W. Armstrong, Hyun Jung Kim, Andrew E. Pink, Joe Gorelick, Mariateresa Rossi, Magdalena Trzeciak, Mette Deleuran, Saeko Nakajima, Vimal H. Prajapati

  • October 19, 2026

Related Content

Efficacy and Safety of Variable-Dose Versus Continuous-Dose Abrocitinib Treatment in Patients with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis

Ivarmacitinib Eased Refractory PCA: Case Report

Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.

Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical Trials